HC Wainwright Estimates Vivani Medical Q1 Earnings

Vivani Medical, Inc. (NASDAQ:VANI - Free Report) - Research analysts at HC Wainwright issued their Q1 2026 EPS estimates for shares of Vivani Medical in a research note issued on Monday, May 19th. HC Wainwright analyst Y. Chen anticipates that the company will earn ($0.09) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $4.00 target price on the stock. The consensus estimate for Vivani Medical's current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Vivani Medical's Q2 2026 earnings at ($0.08) EPS, Q3 2026 earnings at ($0.08) EPS, Q4 2026 earnings at ($0.08) EPS and FY2026 earnings at ($0.33) EPS.

Vivani Medical Price Performance

Shares of NASDAQ:VANI opened at $1.13 on Thursday. The firm has a market capitalization of $66.95 million, a PE ratio of -2.51 and a beta of 2.81. Vivani Medical has a 1 year low of $0.91 and a 1 year high of $2.09. The firm's 50-day moving average is $1.05 and its two-hundred day moving average is $1.16.

Vivani Medical (NASDAQ:VANI - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.01).

Institutional Trading of Vivani Medical

A number of large investors have recently modified their holdings of VANI. Wealthedge Investment Advisors LLC acquired a new position in Vivani Medical during the 4th quarter worth $43,000. Jane Street Group LLC purchased a new position in Vivani Medical in the fourth quarter worth approximately $66,000. Northern Trust Corp grew its stake in shares of Vivani Medical by 19.1% during the fourth quarter. Northern Trust Corp now owns 71,915 shares of the company's stock worth $83,000 after purchasing an additional 11,540 shares in the last quarter. Finally, Connective Capital Management LLC increased its holdings in shares of Vivani Medical by 796.2% in the 1st quarter. Connective Capital Management LLC now owns 162,098 shares of the company's stock valued at $170,000 after acquiring an additional 144,010 shares during the last quarter. Hedge funds and other institutional investors own 6.78% of the company's stock.

Insider Activity at Vivani Medical

In other Vivani Medical news, Director Gregg Williams purchased 44,400 shares of the firm's stock in a transaction on Monday, April 7th. The stock was bought at an average price of $0.99 per share, with a total value of $43,956.00. Following the transaction, the director now directly owns 4,799,200 shares of the company's stock, valued at approximately $4,751,208. This represents a 0.93% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last quarter, insiders acquired 121,662 shares of company stock worth $121,636. Corporate insiders own 46.40% of the company's stock.

About Vivani Medical

Vivani Medical, Inc, a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.